Home / Pharmaceutical company intelligence
SAMI Pharmaceuticals Pvt. Ltd. logo
Pharmaceutical company intelligence

SAMI Pharmaceuticals Pvt. Ltd.

Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer and marketer of branded generic medicines across major therapeutic categories.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check25 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
SAMI Pharmaceuticals (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
34-C, Block-6, P.E.C.H.S., Karachi-75350, Pakistan · 75350
Phone
+92 21 34527490-92
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000072 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Formulation 000731 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Semi Basic Manufacture 000907 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Formulation 000938 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000072 192 linked products · source seen 25 Sep 2026 View source ↗
DML 000938 3 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx203public portfolio records represented
REG152unique registrations represented
IDX24indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR194current validated price records
G64generic molecules in indexed catalogue
DF8dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage96%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixSAMI Pharmaceuticals Pvt. Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026Anti-infectives99 · 51%Cardiovascular24 · 12%Endocrine & metabolic18 · 9%Vitamins, minerals & nutrition10 · 5%Oncology & immunology9 · 5%Hematology & thrombosis9 · 5%Gastrointestinal & hepatology9 · 5%Other therapeutic areas17 · 9%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioSAMI Pharmaceuticals Pvt. Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026195presentationsTablet97 · 50%Injection49 · 25%Capsule16 · 8%Suspension16 · 8%Infusion12 · 6%Solution3 · 2%Other forms2 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionSAMI Pharmaceuticals Pvt. Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026180comparable productsBelow peer median14 · 8%Near peer median60 · 33%Above peer median106 · 59%Company median price position+7.3%Lowest-price equivalents10Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsSAMI Pharmaceuticals Pvt. Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026M/s. Genix Pharma (Pvt) Ltd.41 shared64% overlapMacter International Limited41 shared64% overlapHIGH-Q Pharmaceuticals39 shared61% overlapTABROS PHARMA (PVT). LTD.39 shared61% overlapNabiqasim Industries (Pvt) Ltd.,38 shared59% overlapBosch Pharmaceuticals (Pvt) Ltd.38 shared59% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives99 products · 51%
Cardiovascular24 products · 12%
Endocrine & metabolic18 products · 9%
Vitamins, minerals & nutrition10 products · 5%
Oncology & immunology9 products · 5%
Hematology & thrombosis9 products · 5%
Gastrointestinal & hepatology9 products · 5%
Pain & musculoskeletal9 products · 5%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antivirals20 products · 10%
Antidiabetic medicines17 products · 9%
Third-generation cephalosporins15 products · 8%
Calcium-channel blockers15 products · 8%
Antimalarials12 products · 6%
Macrolide antibacterials12 products · 6%
Fluoroquinolone antibacterials12 products · 6%
Vitamins / minerals / hematinics10 products · 5%
Formulation footprint

Dosage forms

Tablet97 products
Injection49 products
Capsule16 products
Suspension16 products
Infusion12 products
Solution3 products
Drops1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 RYBIORibavirin 11presentations 200 mg, 400 mg, 500 mg, 600 mg · Tablet, Capsule #2 TELARB-PlusTelmisartan + Amlodipine 11presentations 40 mg + 10 mg, 40 mg + 5 mg, 80 mg + 10 mg, 80 mg + 5 mg · Tablet #3 EMPOLIEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #4 GrasilAmikacin 7presentations 100 mg, 25 mg, 25 mg/1 mL, 250 mg · Injection #5 NOVIDATCiprofloxacin 7presentations 125 mg/5 mL, 200 mg/100 mL, 250 mg, 250 mg/5 mL · Suspension, Infusion, Tablet #6 ARILIOTacrolimus 6presentations 0.5 mg, 1 mg, 5 mg · Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median148% of comparable products
Near market median60within ±5% of median
Above market median10659% of comparable products
Lowest-price equivalents10ties included
Company median price position +7.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Fungone 100 mg/50 mLFluconazole · IV infusion · 50ml PKR 3.15/mL-70.5% vs market median ONATO 10 mgAmlodipine · Tablet · 3x10's PKR 10.22/tablet-42.5% vs market median ONATO 10 mgAmlodipine · Tablet · 20's PKR 10.22/tablet-42.5% vs market median CARICEF 100 mg/5 mLCefixime · Suspension · 60 ml PKR 6.82/mL-35.1% vs market median OLMETHATE 1 MIUColistimethate sodium · Injection · 1's PKR 1,108.52/vial/unit-33.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 41shared generics Macter International Limited256 products · 93 generics 41shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 39shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 39shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 38shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 38shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers145Distinct registrations among indexed, published, presentation-validated products only
Verified price observations195
Products with a verified price195
Products with multiple price observations0
Source records with multiple versions188
Latest portfolio source check25 Sep 2026
Latest effective price date4 Aug 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

152 unique registration(s) · 24 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
ACTIM Bisoprolol fumarate 5 mg Tablet 14's 034068 PKR 190.83 PKR 13.63/tablet 16% above median
ACTIM Bisoprolol fumarate 10 mg Tablet 1x28's 034069 PKR 619.75 PKR 22.13/tablet Near median
ACTIM Bisoprolol fumarate 10 mg Tablet 14's 034069 PKR 316.20 PKR 22.59/tablet Near median
ACTIM Bisoprolol fumarate 2.5 mg Tablet 3x10's 045362 PKR 140.03 PKR 4.67/tablet 10% above median
ACTIM Bisoprolol fumarate 2.5 mg Tablet 20's 045362 PKR 93.35 PKR 4.67/tablet 10% above median
ONATO Amlodipine 10 mg Tablet 3x10's 024499 PKR 306.69 PKR 10.22/tablet 42% below median
ONATO Amlodipine 10 mg Tablet 20's 024499 PKR 204.47 PKR 10.22/tablet 42% below median
ONATO Amlodipine 5 mg Tablet 3x10's 027777 PKR 494.02 PKR 16.47/tablet 52% above median
ONATO Amlodipine 5 mg Tablet 20's 027777 PKR 329.35 PKR 16.47/tablet 52% above median
TELARB-H Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 28's 100513 PKR 1,216.47 PKR 43.45/tablet Near median
TELARB-H Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 14's 100513 PKR 640.22 PKR 45.73/tablet Near median
TELARB-H Telmisartan + Hydrochlorothiazide 80 mg + 12.5 mg Tablet 28's 100514 PKR 2,292.50 PKR 81.88/tablet Near median
TELARB-H Telmisartan + Hydrochlorothiazide 80 mg + 12.5 mg Tablet 14's 100514 PKR 1,208.22 PKR 86.30/tablet 6% above median
TELARB-Plus Telmisartan + Amlodipine 40 mg + 5 mg Tablet 14's 100515 PKR 712.53 PKR 50.90/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 5 mg Tablet 30's 100924 PKR 2,042.59 PKR 68.09/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 5 mg Tablet 10's 100924 PKR 681.54 PKR 68.15/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 5 mg Tablet 14's 100924 PKR 954.16 PKR 68.15/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 5 mg Tablet 20's 100924 PKR 1,363.08 PKR 68.15/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 40 mg + 10 mg Tablet 30's 100925 PKR 1,544.84 PKR 51.49/tablet 6% below median
TELARB-Plus Telmisartan + Amlodipine 40 mg + 10 mg Tablet 10's 100925 PKR 559.68 PKR 55.97/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 40 mg + 10 mg Tablet 14's 100925 PKR 805.54 PKR 57.54/tablet 7% above median
TELARB-Plus Telmisartan + Amlodipine 40 mg + 10 mg Tablet 20's 100925 PKR 1,063.62 PKR 53.18/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 10 mg Tablet 14's 100926 PKR 1,187.54 PKR 84.82/tablet Near median
TELARB-Plus Telmisartan + Amlodipine 80 mg + 10 mg Tablet 10's 100926 PKR 846.76 PKR 84.68/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). SAMI Pharmaceuticals Pvt. Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/sami-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.